US 7,517,527 B2
Immunotoxin with in vivo T cell suppressant activity and methods of use
David M. Neville, Jr., Bethesda, Md. (US); Jerry Todd Thompson, Goose Creek, S.C. (US); Huaizhong Hu, Bethesda, Md. (US); and Shenglin Ma, Bethesda, Md. (US)
Assigned to The United States of America as represented by the Department of Health and Human Services, Washington, D.C. (US)
Filed on Sep. 03, 1999, as Appl. No. 9/389,565.
Application 09/389565 is a continuation of application No. 08/739703, filed on Oct. 29, 1996, abandoned.
Claims priority of provisional application 60/008104, filed on Oct. 30, 1995.
Prior Publication US 2003/0157093 A1, Aug. 21, 2003
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); C07K 16/00 (2006.01); C12P 21/08 (2006.01)
U.S. Cl. 424—183.1  [530/388.75; 530/391.7] 5 Claims
 
1. A fusion immunotoxin comprising a single-chain variable region of an anti-CD3 antibody linked to a toxin moiety, wherein the anti-CD3 antibody is UCHT1, wherein the diphtheria toxin moiety is DT390.